Announced details
Treatment of acute kidney injury (AKI) following cardiovascular surgery
Results from a Phase I trial in healthy adults suggesting good tolerability and safety
Recipient of the clinical trial notification
An independent administrative agency responsible for the approval review and safety measures for pharmaceuticals, medical devices and other products
No impact on earnings for the fiscal year ending December 2026
The company does not address Contract Value / Offering price.
Machado MN, et al. Rev Bras Cir Cardiovasc. 29: 299–307 (2014)
| Item | Details |
|---|---|
| Names of Products / Services Covered | TMS-008 |
| Counterparty | Pharmaceuticals and Medical Devices Agency (PMDA) |
| Counterparty overview | An independent administrative agency responsible for the approval review and safety measures for pharmaceuticals, medical devices and other products |
| Relationship with the Company | Recipient of the clinical trial notification |
| Launch date | The clinical trial notification was submitted on 30 September 2026. The planned start date for the trial is Not disclosed |
| Applicable area | Treatment of acute kidney injury (AKI) following cardiovascular surgery |
| Usage history | Results from a Phase I trial in healthy adults suggesting good tolerability and safety |
| Impact on Business Performance | No impact on earnings for the fiscal year ending December 2026 |
| Source | Machado MN, et al. Rev Bras Cir Cardiovasc. 29: 299–307 (2014) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The costs of this trial for the fiscal year ending December 2026 are included in the previously disclosed range of research and development expenses for the current fiscal year, so there will be no impact on earnings.